Logo image of AAPG

ASCENTAGE PHARMA GR-ADR (AAPG) Stock Fundamental Analysis

NASDAQ:AAPG - Nasdaq - ADR - Currency: USD

25.35  +0.92 (+3.78%)

Fundamental Rating

3

AAPG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. AAPG has a bad profitability rating. Also its financial health evaluation is rather negative. AAPG shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AAPG had negative earnings in the past year.
AAPG had a negative operating cash flow in the past year.
In the past 5 years AAPG always reported negative net income.
AAPG had a negative operating cash flow in each of the past 5 years.
AAPG Yearly Net Income VS EBIT VS OCF VS FCFAAPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500M -1B

1.2 Ratios

AAPG has a better Return On Assets (-15.49%) than 81.07% of its industry peers.
AAPG has a worse Return On Equity (-153.46%) than 63.21% of its industry peers.
Industry RankSector Rank
ROA -15.49%
ROE -153.46%
ROIC N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
AAPG Yearly ROA, ROE, ROICAAPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

The Gross Margin of AAPG (97.03%) is better than 96.79% of its industry peers.
AAPG's Gross Margin has improved in the last couple of years.
AAPG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
AAPG Yearly Profit, Operating, Gross MarginsAAPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

AAPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AAPG has been increased compared to 1 year ago.
AAPG has more shares outstanding than it did 5 years ago.
AAPG has a better debt/assets ratio than last year.
AAPG Yearly Shares OutstandingAAPG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AAPG Yearly Total Debt VS Total AssetsAAPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

Based on the Altman-Z score of 0.65, we must say that AAPG is in the distress zone and has some risk of bankruptcy.
AAPG's Altman-Z score of 0.65 is fine compared to the rest of the industry. AAPG outperforms 67.86% of its industry peers.
AAPG has a Debt/Equity ratio of 4.46. This is a high value indicating a heavy dependency on external financing.
AAPG's Debt to Equity ratio of 4.46 is on the low side compared to the rest of the industry. AAPG is outperformed by 84.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.46
Debt/FCF N/A
Altman-Z 0.65
ROIC/WACCN/A
WACC7.83%
AAPG Yearly LT Debt VS Equity VS FCFAAPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

A Current Ratio of 1.26 indicates that AAPG should not have too much problems paying its short term obligations.
AAPG has a Current ratio of 1.26. This is amonst the worse of the industry: AAPG underperforms 85.00% of its industry peers.
A Quick Ratio of 1.26 indicates that AAPG should not have too much problems paying its short term obligations.
AAPG's Quick ratio of 1.26 is on the low side compared to the rest of the industry. AAPG is outperformed by 84.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.26
AAPG Yearly Current Assets VS Current LiabilitesAAPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

AAPG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.43%, which is quite impressive.
The Revenue has grown by 341.77% in the past year. This is a very strong growth!
The Revenue has been growing by 132.25% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)61.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.86%
Revenue 1Y (TTM)341.77%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%97.9%

3.2 Future

The Earnings Per Share is expected to grow by 24.96% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 23.37% on average over the next years. This is a very strong growth
EPS Next Y-182.73%
EPS Next 2Y103.09%
EPS Next 3Y24.96%
EPS Next 5YN/A
Revenue Next Year-48.7%
Revenue Next 2Y58.4%
Revenue Next 3Y17.2%
Revenue Next 5Y23.37%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AAPG Yearly Revenue VS EstimatesAAPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AAPG Yearly EPS VS EstimatesAAPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AAPG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AAPG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AAPG Price Earnings VS Forward Price EarningsAAPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AAPG Per share dataAAPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as AAPG's earnings are expected to grow with 24.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.09%
EPS Next 3Y24.96%

More info and screens

0

5. Dividend

5.1 Amount

AAPG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASCENTAGE PHARMA GR-ADR

NASDAQ:AAPG (5/29/2025, 8:00:00 PM)

25.35

+0.92 (+3.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/bmo
Earnings (Next)N/A N/A
Inst Owners7.36%
Inst Owner ChangeN/A
Ins Owners13.63%
Ins Owner ChangeN/A
Market Cap2.21B
Analysts87.14
Price Target26.43 (4.26%)
Short Float %0.03%
Short Ratio0.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.96%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.13%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.2
P/FCF N/A
P/OCF N/A
P/B 60.12
P/tB 97.15
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS1.57
BVpS0.42
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.49%
ROE -153.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.03%
FCFM N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 4.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.07%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.26
Quick Ratio 1.26
Altman-Z 0.65
F-Score5
WACC7.83%
ROIC/WACCN/A
Cap/Depr(3y)161.69%
Cap/Depr(5y)588.72%
Cap/Sales(3y)47.03%
Cap/Sales(5y)745.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.86%
EPS Next Y-182.73%
EPS Next 2Y103.09%
EPS Next 3Y24.96%
EPS Next 5YN/A
Revenue 1Y (TTM)341.77%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%97.9%
Revenue Next Year-48.7%
Revenue Next 2Y58.4%
Revenue Next 3Y17.2%
Revenue Next 5Y23.37%
EBIT growth 1Y57.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-259.46%
EBIT Next 3Y26%
EBIT Next 5YN/A
FCF growth 1Y82.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y84.66%
OCF growth 3YN/A
OCF growth 5YN/A